Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

被引：0

作者：

Kulasekararaj, Austin G. ^{[1
]}

Mohamedali, Azim M. ^{[2
]}

Smith, Alexander E. ^{[2
]}

Lea, Nicholas C. ^{[2
]}

Kizilors, Aytug ^{[2
]}

Abdallah, Atiyeh ^{[1
]}

Nasser, Erik E. ^{[2
]}

Mian, Syed A. ^{[2
]}

Yiu, Richard ^{[1
]}

Gaken, Joop ^{[2
]}

Pomplun, Sabine ^{[2
]}

Jiang, Jie ^{[1
]}

Gaymes, Terry J. ^{[2
]}

Pasipanodya, Patience ^{[1
]}

Hayden, Janet ^{[1
]}

Ireland, Robin M. ^{[1
]}

Lim, ZiYi ^{[1
]}

Ho, Aloysius Y. ^{[1
]}

Marsh, Judith C. W. ^{[1
]}

Mufti, Ghulam J. ^{[2
]}

机构：

[1] Kings Coll Hosp, Dept Haematol Med, London, England

[2] Kings Coll London, Dept Haematol Med, London WC2R 2LS, England

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：61 / 61

页数：1

共 50 条

[31] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
Kuendgen, Andrea
Mueller-Thomas, Catharina
Urbaniak, Petra
Lauseker, Michael
Haferlach, Torsten
Alpermann, Tamara
Albuquerque, Andreia
Kohlmann, Alexander
Schnittger, Susanne
Hildebrandt, Barbara
Royer-Pokora, Brigitte
Gattermann, Norbert
Haas, Rainer
Germing, Ulrich
Goetze, Katharina
BLOOD, 2013, 122 (21)
[32] Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Bally, Cecile
Ades, Lionel
Renneville, Aline
Sebert, Marie
Eclache, Virginie
Preudhomme, Claude
Mozziconacci, Marie-Joelle
de The, Hugues
Lehmann-Che, Jacqueline
Fenaux, Pierre
LEUKEMIA RESEARCH, 2014, 38 (07) : 751 - 755
[33] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
Kenealy, Melita K.
Seymour, John F.
Linda, Cowan
Milner, Alvin
Giri, Pratyush
Ho, Shir-Jing
Benson, Warwick
Nicol, Andrew
Campbell, Philip
Prosser, Ian
Underhill, Craig
Cunningham, Ilona
Mills, Anthony K.
Szer, Jeffrey
Presgrave, Peter
Filshie, Robin
BLOOD, 2009, 114 (22) : 695 - 695
[34] Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis
Kumar, Ambuj
List, Alan F.
Hozo, Iztok
Komrokji, Rami
Djulbegovic, Benjamin
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 340 - 342
[35] Allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) after pretransplant 5-azacitidine
Field, Teresa
Alsina, Melissa
Ayala, Ernesto
Fernandez, Hugo
Janssen, William
Karfan-Dabaja, Mohammed
Lancer, Jeffery
Melchert, Mafda
Raychaudhuri, Jyoti
Sullivan, Daniel
List, Alan
Anasetti, Claudio
Poling, William
Perkins, Janelle
BLOOD, 2007, 110 (11) : 338B - 338B
[36] A pilot trial of anti-KIR antibody with or without 5-azacitidine for myelodysplastic syndrome.
Yalniz, Fevzi Firat
Daver, Naval Guastad
Kornblau, Steven Mitchell
Ohanian, Maro
Borthakur, Gautam
Dinardo, Courtney Denton
Konopleva, Marina
Burger, Jan Andreas
Gasior, Yvonne
Pierce, Sherry
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
Borthakur, Gautam
El Ahdab, Samih
Ravandi, Farhad
Faderl, Stefan
Ferrajoli, Alessandra
Newman, Beth
Issa, Jean-Pierre
Kantarjian, Hagop
LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 690 - 695
[38] Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine
Lai, Shiue-Wei
Huang, Tzu-Chuan
Ye, Ren-Hua
Wu, Yi-Ying
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) : 273 - 276
[39] The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
Takahiro Kamiya
Tomonori Nakazato
Medical Oncology, 2019, 36
[40] The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
Kamiya, Takahiro
Nakazato, Tomonori
MEDICAL ONCOLOGY, 2019, 36 (03)

← 1 2 3 4 5 →